Clinical Development Programs



Breast Cancer


Our flagship program is developing GLG-302 (an NCE) and GLG-801 (a repurposed compound) in Triple Negative Breast Cancer (TNBC). Both have shown excellent preclinical activity as solitary or combinatorial agents against several breast cell lines and have demonstrated exciting tumor mass reductions in-vivo.  Non-GLP toxicology has been completed in dogs and rats with excellent tolerability and we are in the process of initiating a TNBC Phase I/II clinical trial with GLG-801. 


Chronic Lymphocytic Leukemia


Other programs include an ongoing Phase I/II trial of GLG-801 in Chronic Lymphocytic Leukemia (CLL) that has shown a favorable response profile and therapeutic index.


Ovarian Cancer


In Q42017 we initiated a preclinical program to apply our Gx-C3 platform for precision, patient-centric treatment of ovarian cancer.


Diffuse Intrinsic Pontine Glioma


We have initiated a Phase I/II study of GLG-801 for childhood Diffuse Intrinsic Pontine Glioma (DIPG) and other pediatric brain tumors, and in 3Q2018 we embarked on a grant funded mission to apply our Gx-C3 platform to DIPG in order to elevate the standard of care for this indication.